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A scientist’s first commandment: 
“thou shalt not take credit for thy 
junior collaborators’ work”
— Max Perutz [1]
The story of streptomycin is no 
ordinary tale. On August 23rd, 1943, 
in an isolated basement room, a 
brave and determined graduate 
student, Albert Schatz, began his 
quest to cure tuberculosis. He, with 
his soil bacteria and virulent tubercle 
bacilli, was banished to that room 
by his supervisor Selman Waksman, 
who, like everyone else, dreaded the 
infection. Waksman never visited 
Schatz’s workroom. Schatz’s moment 
of discovery of an effective antibiotic 
was a key step in developing a 
treatment for tuberculosis; in the 
longer term streptomycin had to be 
combined with other drugs, but the 
antibiotic saved the lives and spared 
the suffering of millions. Streptomycin 
meant the end of innumerable 
sanatoria, institutions funded by 
misplaced hope and peopled by the 
forlorn [2]. Peter Pringle’s excellent 
book Experiment Eleven details how 
a simple discovery dominated and 
remodelled the lives of both these two 
scientists. It tells of a bitter legal fight 
over credit and a misallocated Nobel 
Prize. And, like the best of dramas, 
it reaches outwards, to illuminate 
scientific behaviour at the time, and 
forwards, to change our perceptions 
of scientific ethics today. 
Pringle has spent three years 
excavating clues from many sources, 
both personal and public; his search 
was helped by Milton Wainwright, 
who first reported extensively on the 
injustice done to Schatz [3]. Now 
Pringle, with the help of archivists 
at Rutgers University Libraries, 
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*Quotations shown unattributed in the text are 
from Experiment Eleven.especially Erika Gorder, has found 
Schatz’s lost labnotes. He also 
mines records from the Mayo Clinic 
and from Merck and details the 
machinations of the public relations 
department at Rutgers as well as 
its legal representatives. With the 
willing help of Schatz’s wife Vivian 
and other living witnesses Pringle 
has dug up dirt and written a 
devastating account. It is remarkable 
that Waksman alone received the 
1952 Nobel Prize for physiology 
or medicine: it was given for “his 
discovery of streptomycin, the 
first antibiotic effective against 
tuberculosis” [4] and perhaps not 
so remarkable that subsequently 
“Schatz’s contribution was soon 
forgotten” [1].
Schatz was 22 when he was drafted 
from Waksman’s lab in 1942 and sent 
to the Army Air Forces hospital at 
Miami. He saw the effects of infection 
on the wounded and although 
penicillin had just become available, 
it did not work against Gram-negative 
bacteria, such as those causing 
typhoid and cholera, or against 
Mycobacterium tuberculosis (TB). 
Schatz felt powerless as he spent 
his free time comforting the dying. 
When he returned to Waksman’s lab 
in the summer of 1943 he began a 
personal mission to find a new and 
wide spectrum antibiotic. In August 
he undertook ‘experiment eleven’ 
where he tried a different method of 
sampling and found a promising effect 
of the soil bacterium Actinomyces 
griseus, some of which came from a 
swab of a chicken’s throat given to 
him by another student, Doris Jones. 
In October, an extract was tested 
in chicken eggs and found to kill 
typhoid bacteria without harming the 
eggs (previous antibiotic candidates 
isolated in Waksman’s lab had proved 
highly toxic). 
Then Schatz wanted to test the 
new antibiotic against pathogenic 
TB bacteria. Waksman acquired 
some of these bacteria and Schatz 
personally worked out how to isolate 
enough of the new chemical and did 
the bacteriological tests. He worked 
day and night, often snatching sleep 
on the floor of the lab. Overdoing it, 
Schatz became ill and collapsed with 
pneumonia: “Waksman was the only 
member of the staff who didn’t visit 
him”* in hospital. But streptomycin 
inactivated the bacteria and Schatz 
was so elated he sealed up some test tubes and gave them to his mother 
as a memento! Schatz then isolated 
enough streptomycin for trials by 
William Feldman and Corwin Hinshaw 
at the Mayo clinic; they tried the 
antibiotic on guinea pigs infected with 
TB. Streptomycin was not toxic and 
the guinea pigs were cured. Tests on 
humans soon followed; the first life to 
be saved was that of a two-week-old 
baby in September 1944.
Pringle then tells us the history 
of the commercialisation of 
streptomycin; it had many twists 
and turns. But the public story of the 
discovery was subject to continuous 
modification as Waksman rewrote 
history. Don’t get me wrong, I believe 
Waksman deserved credit; it was 
his lab and by following the lead 
from Russian researchers, he had 
doggedly searched for antibiotics 
produced by soil microbes long 
before Schatz arrived, he organised 
the collaboration with the Mayo clinic, 
he set up the commercialisation with 
Merck, he did the politics. However, 
the moment of discovery belonged to 
Schatz: he put his life on the line, he 
did the research, he discovered and 
then purified the antibiotic and did the 
first crucial tests. 
Waksman’s subsequent 
campaign is meticulously detailed 
in Pringle’s book and Waksman’s 
misappropriation emerges step 
by step with painful clarity. Pringle 
describes how the self-serving 
combination of Waksman himself 
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at Rutgers together undertook an 
ultimately successful siege on 
the Nobel Prize. They invented a 
“parable”, a fraudulent myth about 
a robotic and nameless assistant 
who followed orders from the top but 
contributed no more to the discovery 
than the chicken from which 
the bacteria were isolated. They 
misinformed gullible commentators, 
they took advantage of the tendency 
of journalists to simplify and to 
lionise, they twisted the truth, they 
rubbished the facts, they hid the 
money-trail, they covered up the 
original patent (which belonged to 
both Schatz and Waksman), it goes 
on and on. 
I read Pringle’s well-documented 
account open-mouthed as I 
witnessed Schatz’s reputation and his 
brave contribution being obliterated. 
Waksman must have been conscious 
of what he was doing, he avoided 
mentioning Schatz on every occasion, 
including his first public lecture on 
streptomycin, at the Mayo Clinic in 
1944. In that talk he relied on using 
the royal “we”, and mentioned no 
collaborators at all, even Feldman and 
Hinshaw, who were in the audience! 
He painted a meretricious picture 
of himself as an idealistic hero who 
gave any money away. But actually 
he had been secretly receiving 
royalties from Merck, some $350,000 
dollars (1940s!) without telling Schatz. 
Perhaps feeling some guilt, he offered 
Schatz small sweeteners of three 
$500 dollar cheques but he did not 
tell Schatz where the money came 
from. Schatz assumed they were 
personal gifts from Waksman and at 
first refused to accept. 
No surprise then that Schatz was 
outraged when he later found out that 
Waksman had been double-crossing 
him. Schatz was so upset he went 
to the law to reclaim his status as a 
joint discoverer. The legal arguments 
are beautifully spelt out by Pringle: 
because the investigation uncovered 
so many inconsistencies and untruths 
in Waksman’s reinvention of the past, 
the lawyers for Rutgers got cold feet 
and they settled: Schatz was legally 
recognised as a co-discoverer of 
streptomycin on December 30th 1950.
In 1950, Waksman went travelling 
on an extensive campaign for the 
Nobel Prize in Europe, while the 
image-building publicity continued 
in the press at home. The American Magazine titled their puff: “He turned 
his back on a million dollars: An 
intimate glimpse of a distinguished 
scientist who passed up a sure 
fortune for the greater reward of 
freeing mankind from disease” [5]. 
Schatz was not mentioned. So it 
was that the Nobel was awarded in 
1952 to Waksman alone. Feldman 
was surprised and wondered 
in a letter if the prize had been 
awarded to Waksman for a “long 
professional career pertaining to 
the microbiological investigation of 
the soil from which streptomycin 
finally emerged”. But that was not 
the justification given nor could it 
have been because of Alfred Nobel’s 
will — Nobel Prizes then and now are 
given for a specific discovery, not for 
a laudable career and not for courtly 
behaviour! 
In my opinion, streptomycin was 
Schatz’s discovery and Waksman’s 
lab and infrastructure made it 
possible (as did the chicken one 
could add, but that “counterparable” 
would also be very unfair). After 
the announcement, Waksman and 
supporters attempted to influence 
the Nobel Assembly to change their 
justification for the prize and indeed 
at the ceremony in Stockholm there 
was a shift to recognise the “parable” 
that Waksman had originally invented, 
and also a hint that the prize was for 
a long effort. This reinvention was 
eagerly underwritten by Waksman 
in his acceptance lecture when he 
managed to avoid mentioning Schatz 
at all; although there was an appendix 
where Schatz was listed along with 
others, half of whom “had not even 
been at Rutgers when Schatz had 
discovered streptomycin”. “This is 
how Waksman wanted the world to 
see Albert Schatz”.
Indeed, this was largely how the 
world subsequently saw Schatz, 
and also as a litigious student who 
acted above his station in suing his 
supervisor; “many of Waksman’s 
contemporaries took his side 
without apparently acquainting 
themselves with the details of the 
case”[3]. Schatz had trouble finding 
employment and his discovery was 
not properly recognised for the rest of 
his career, until long after Waksmans 
death in 1973 when, in 1994, 
Rutgers awarded Schatz their most 
prestigious medal.
So with hindsight, who should 
have received the 1952 Nobel Prize? It becomes clear from this book 
and from Max Perutz’s account 
that the prize might in justice have 
gone to Schatz, Waksman and 
Jorgen Lehmann for two separate 
discoveries. Lehmann used brilliant 
logic to invent PAS, a drug that, 
in combination with streptomycin, 
cured patients with TB. Stockholm’s 
records show that Lehmann and 
Waksman were nominated in 1951 
and 1952, and Schatz in 1952 for the 
prize. In general there are criticisms 
one can make of the decisions of the 
Nobel committee at the Karolinska 
Institutet; for example, one could 
say that a discovery they choose 
to honour is not the right one; 
but I think that kind of criticism is 
inappropriate; it is for them not us 
to make that selection, there are so 
many valuable advances in science 
to choose between. But to fix on a 
specific discovery and then not to 
recognise the real discoverer(s), that 
I think should be open to question. 
Pringle’s book makes it clear why 
the Karolinska were misled and I 
have also seen the opinion of Einar 
Hammersten, the main advisor to the 
committee in 1951/2. His opinion was 
weakened by a lack of knowledge 
of how the work was done and by a 
questionable tendency to include the 
rank of each candidate as a factor in 
his considerations.
There may be an endemic 
injustice in the choice of Nobel 
laureates and other awardees: that 
senior scientists — and it is they 
who nominate, are consulted and 
decide — tend to overlook junior 
candidates. Apart from the Schatz 
case, it happened with the omission 
of the student Charles Best from the 
1922 prize for insulin, an error which 
was acknowledged 50 years later by 
the Nobel Foundation [6]. It may have 
happened with Jocelyn Bell Burnell, 
who was also a student when she 
found pulsars with her supervisor 
Anthony Hewish. And it appears to 
have happened this year in respect 
of part of the 2011 physiology or 
medicine Nobel Prize. The prize 
concerns innate immunity, a field 
that began with Hans Boman and 
colleagues in Sweden, who studied 
how insects protect themselves 
against bacteria and fungi. For this 
year’s Nobel Prize, credit was given 
particularly for a paper in 1996 on 
Drosophila genetics; it presented 
clear evidence that the Toll pathway 
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Eric Davidson graduated from 
the University of Pennsylvania in 
1954 and received his PhD from 
Rockefeller University in 1963. 
He remained at Rockefeller until 
1971 when he moved to Caltech in 
Pasadena, California. He was elected 
to the U.S. National Academy of 
Sciences in 1985, and is at present 
Norman Chandler Professor of 
Cell Biology in the Division of 
Biology, Caltech. He is the author 
of 5 books and over 400 papers on 
developmental gene regulation and 
evolution of genomic programs for 
development. For the last decade 
his work has focused on theory and 
operation of developmental gene 
regulatory networks. 
What specific events in your early 
life most strongly affected your 
path into a career in biology? All 
developmental processes occur 
stepwise, and so did my own 
trajectory. Though from my earliest 
recollections I was always interested 
in science, I went to typically 
unedifying, casually violent and 
prejudiced provincial 1940s–early 
1950s American public schools, 
from which only a tiny fraction of 
male students ever went to college, 
and where there were no particular 
scientific opportunities available. 
But the day I walked into 10th grade 
biology class, I saw an elderly and 
kindly, intelligent-looking teacher 
in a long severe dress and heavy 
black shoes. She was Miss Krum. A 
fateful idea popped into my mind: I 
offered to her to make all the class 
lab preps for the year, if I would be 
excused from weekly quizzes. She 
looked at me over the tops of her 
old fashioned thick glasses, and 
said “Do you know how to make 
microscope preps, young man? 
“Yes Ma’am” said I, and went home 
and fixed up some stained onion 
skin and a few paramecia etc. on a 
microscope a family friend had given 
me one Christmas; and that was 
it: by the end of that year, and the 
weekly experience of looking long 
and hard at some new preparation 
of fascinating cells or eggs, or 
studying ancient  teaching sections, 
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I was hooked for life. And so that 
summer I went to Provincetown, 
Massachussetts as always, for that 
was the location of the art school 
of my father, Morris Davidson, 
who was then a famous painter. 
He made an arrangement with one 
of his art students that by another 
serendipity a week later had landed 
me in a wonderful laboratory at 
the Woods Hole Marine Biology 
Laboratory (MBL), just at the other 
end of Cape Cod. The student was 
Ellen Donovan, the wife of Prof. L.V. 
Heilbrunn and an artist in her own 
right. L.V. was an MBL scientific 
institution. I was to wash dishes in 
his lab, and to make my keep, at 
night collect whatever biological 
wastes each lab had put outside 
its door, ground up horse meat, 
empty clam shells, dead sea urchins, 
whatever. But when I walked in the 
door, ‘Boss’, as L.V. was universally 
known, growled at me “You are 
going to do research if you are going 
to be in my lab!” He gave me a 
problem, and a clue to the possible 
answer, and the rest is history. It 
was 1953, and my first publication 
describing the successful conclusion 
of that summer’s work was in the 
1954 Biological Bulletin Abstracts 
of the previous summer’s research 
proceedings. In August, I had 
had the terrifying experience of 
presenting this work in the big 
auditorium before the whole MBL 
Corporation. But on the strength of 
that project I later that year became 
a Westinghouse Science Talent 
Search Winner, and on the strength 
of that I got to go to the University of 
Photo: Lance Hayashida.is instrumental against infection. 
The prize was given to the lab chief, 
Jules Hoffmann. But the first author 
on the paper, Bruno Lemaitre, has 
argued that he initiated the project 
and planned it, that he made the 
discovery that mutations in the Toll 
pathway rendered a fly impotent 
against infection, that he wrote up 
the first version of the paper and that 
Hoffmann’s scientific contribution 
to the discovery itself was largely 
limited to improving the paper’s 
style [7]. And the facts asserted 
by Lemaitre are not disputed. It is 
documented that Hoffmann never 
properly acknowledged Lemaitre’s 
contribution to the Toll discovery. 
Jeremy Garwood has researched the 
matter and alleges that Hoffmann 
also manipulated perceptions, 
just as Waksman had done half a 
century before, by writing numerous 
reviews, giving many lectures, making 
copious use of the royal “we” and 
by networking to raise his own 
profile at the expense of his junior 
collaborators [8].
Why worry about who receives 
Nobel Prizes? I think we should 
because the prizes act so powerfully 
to define what we value in science; 
the prizes create role models whom 
scientists try to emulate, they draw 
attention to the greatest discoveries 
and announce who is responsible 
for them. The choices of particular 
laureates often receive worldwide 
approbation but, whether they do 
or do not, they should be open 
to scrutiny. For in Nobel’s will his 
express intention was clear: “the most 
worthy shall receive the prize” [6].
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